TrialBMC medicine2025

Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial.

Yaofei Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.